News | June 23, 2025
Cohance Lifesciences to sell CR Bio assets to Chromo Laboratories India for Rs. 16 Cr
The CR Bio unit represents a non-core legacy asset with limited strategic alignment to our core CDMO operations
The CR Bio unit represents a non-core legacy asset with limited strategic alignment to our core CDMO operations
The transaction is expected to close in Q2 FY 2026
The proceeds from the QIP will be utiized for purchase of outstanding optionally convertible debentures
TEMPLE, a Phase 3 multicenter, randomized, double-blind, head-to-head study, evaluated the tolerability, safety and efficacy of atogepant compared to topiramate for the preventive treatment of migraine in adult patients with a history of four or more migraine days per month
BRAVE study will explore the potential of omaveloxolone to address the critical unmet need of the pediatric FA population
The GMP-compliant facility with automated environmental monitoring accommodates both white room and class 7 and 8 cleanroom space
Sun Pharma gets 8 observations from USFDA for Halol facility
The company received one observation in the Form-483
Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies
The companies aim to create customized AI models and agents that Novo Nordisk can use for early research and clinical development
Subscribe To Our Newsletter & Stay Updated
